Vigil Neuroscience (VIGL) News Today $1.62 +0.02 (+1.25%) As of 11:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Blair William & Co. IL Buys Shares of 323,900 Vigil Neuroscience, Inc. (NASDAQ:VIGL)Blair William & Co. IL purchased a new stake in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 323,900 shares of the company's stock,April 6, 2025 | marketbeat.comVigil presents data on oral small molecule program including VG-3927April 3, 2025 | markets.businessinsider.comWilliam Blair Remains a Buy on Vigil Neuroscience Inc (VIGL)April 3, 2025 | markets.businessinsider.comVigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International ConferenceApril 2, 2025 | globenewswire.comVigil Neuroscience Reports 2024 Results and Clinical ProgressApril 2, 2025 | tipranks.comVigil Neuroscience files to sell 5.38M shares of common stock for holdersApril 1, 2025 | markets.businessinsider.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Large Drop in Short InterestVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 419,400 shares, a decrease of 25.6% from the February 28th total of 564,000 shares. Approximately 1.9% of the company's stock are short sold. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is presently 0.4 days.March 31, 2025 | marketbeat.comVigil Neuroscience (VIGL) to Release Earnings on TuesdayVigil Neuroscience (NASDAQ:VIGL) will be releasing earnings before the market opens on Tuesday, March 25, Financial Modeling Prep reports.March 18, 2025 | marketbeat.comFY2029 Earnings Forecast for VIGL Issued By WedbushVigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Vigil Neuroscience in a note issued to investors on Thursday, March 13th. Wedbush analyst L. Chico anticipates that the company will earn $1.40 per share for the yeaMarch 17, 2025 | marketbeat.comQ1 Earnings Estimate for VIGL Issued By William BlairVigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Vigil Neuroscience in a research report issued on Thursday, March 13th. William Blair analyst S. Schram forecasts that the company will earn $0.49March 17, 2025 | marketbeat.comWedbush Issues Pessimistic Forecast for Vigil Neuroscience (NASDAQ:VIGL) Stock PriceWedbush cut their target price on shares of Vigil Neuroscience from $24.00 to $13.00 and set an "outperform" rating on the stock in a report on Friday.March 15, 2025 | marketbeat.comVigil Neuroscience (NASDAQ:VIGL) Given New $14.00 Price Target at HC WainwrightHC Wainwright cut their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a report on Friday.March 15, 2025 | marketbeat.comVigil Neuroscience price target lowered to $14 from $17 at H.C. WainwrightMarch 14, 2025 | markets.businessinsider.comVigil Neuroscience price target lowered to $13 from $24 at WedbushMarch 14, 2025 | markets.businessinsider.comVigil Neuroscience (NASDAQ:VIGL) Announces Earnings ResultsVigil Neuroscience (NASDAQ:VIGL - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.08).March 14, 2025 | marketbeat.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest UpdateVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) saw a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 564,000 shares, a decline of 44.7% from the February 13th total of 1,020,000 shares. Approximately 2.9% of the company's stock are short sold. Based on an average daily trading volume, of 1,030,000 shares, the short-interest ratio is presently 0.5 days.March 14, 2025 | marketbeat.comVigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share DilutionMarch 14, 2025 | tipranks.comVigil Neuroscience, Inc.: Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business UpdatesMarch 13, 2025 | finanznachrichten.deVigil Neuroscience reports Q4 EPS (57c), consensus (47c)March 13, 2025 | markets.businessinsider.comVigil Neuroscience sees cash runway into 2026March 13, 2025 | markets.businessinsider.comVigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business UpdatesMarch 13, 2025 | globenewswire.comVigil Neuroscience to Present at the Stifel 2025 Virtual CNS ForumMarch 11, 2025 | globenewswire.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 43.6% in FebruaryVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) saw a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 1,020,000 shares, a drop of 43.6% from the January 31st total of 1,810,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the short-interest ratio is presently 1.0 days. Approximately 5.2% of the shares of the company are sold short.March 2, 2025 | marketbeat.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)February 20, 2025 | prnewswire.comabrdn plc Buys 293,461 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)abrdn plc increased its stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 124.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 528,472 shares of the company's stock after buying an additional 293,461 sharFebruary 11, 2025 | marketbeat.comVigil Neuroscience Inc (VIGL) Receives a Buy from Stifel NicolausFebruary 10, 2025 | markets.businessinsider.comVigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech ConferenceJanuary 30, 2025 | globenewswire.comVigil Neuroscience reports data from Phase 1 trial on VG-3927January 24, 2025 | markets.businessinsider.comVigil Neuroscience (NASDAQ:VIGL) Receives "Buy" Rating from GuggenheimGuggenheim reiterated a "buy" rating on shares of Vigil Neuroscience in a research report on Friday.January 24, 2025 | marketbeat.comVigil Neuroscience: Now A 'Hold' Based On Two New Pipeline DevelopmentsJanuary 24, 2025 | seekingalpha.comVigil Neuroscience shares rise on positive Alzheimer's trial dataJanuary 23, 2025 | msn.comVigil Neuroscience’s VG-3927: Promising Phase 1 Results and Strategic Positioning for Phase 2January 23, 2025 | markets.businessinsider.comOptimistic Outlook for Vigil Neuroscience Inc: Promising Phase 1 Results and Strategic Partnership Potential for VG-3927January 23, 2025 | markets.businessinsider.comVigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s DiseaseJanuary 23, 2025 | finance.yahoo.comVigil Neuroscience gains as Alzheimer’s drug reaches mid-stage trialJanuary 23, 2025 | msn.comHC Wainwright Reiterates "Buy" Rating for Vigil Neuroscience (NASDAQ:VIGL)HC Wainwright restated a "buy" rating and set a $17.00 price objective on shares of Vigil Neuroscience in a research report on Thursday.January 23, 2025 | marketbeat.comVigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's DiseaseJanuary 23, 2025 | globenewswire.comQ4 Earnings Forecast for VIGL Issued By William BlairVigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Research analysts at William Blair issued their Q4 2024 earnings estimates for Vigil Neuroscience in a research report issued on Wednesday, January 8th. William Blair analyst S. Schram forecasts that the company will post earnings of ($0.20)January 13, 2025 | marketbeat.comVigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 MilestonesJanuary 8, 2025 | globenewswire.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd Purchases 12,000 SharesVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) Director Haeberlein Samantha L. Budd purchased 12,000 shares of the firm's stock in a transaction dated Thursday, December 19th. The shares were bought at an average price of $1.71 per share, with a total value of $20,520.00. Following the purchase, the director now owns 12,000 shares in the company, valued at $20,520. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.December 19, 2024 | marketbeat.comBuy Rating for Vigil Neuroscience Inc: Confidence in Microglial Biology Strategy Amid Market ChallengesDecember 10, 2024 | markets.businessinsider.comInsider Buying: Vigil Neuroscience, Inc. (NASDAQ:VIGL) CEO Buys 5,000 Shares of StockDecember 6, 2024 | insidertrades.comEquities Analysts Issue Forecasts for VIGL FY2024 EarningsVigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Equities researchers at William Blair issued their FY2024 earnings estimates for shares of Vigil Neuroscience in a report issued on Tuesday, December 3rd. William Blair analyst S. Schram forecasts that the company will earn ($2.00) per shareDecember 6, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN), Trevi Therapeutics (TRVI) and Vigil Neuroscience Inc (VIGL)December 5, 2024 | markets.businessinsider.comWilliam Blair Initiates Coverage of Vigil Neuroscience (VIGL) with Outperform RecommendationDecember 5, 2024 | msn.comVigil Neuroscience: Down On A Competitor's FailureDecember 3, 2024 | seekingalpha.comOptimistic Buy Rating for Vigil Neuroscience Amid Market OverreactionNovember 28, 2024 | markets.businessinsider.comPromising Potential of Vigil Neuroscience’s VG-3927 in Alzheimer’s Treatment with a Buy Rating and $17 Price TargetNovember 26, 2024 | markets.businessinsider.comVigil Neuroscience (NASDAQ:VIGL) Given "Market Outperform" Rating at JMP SecuritiesJMP Securities restated a "market outperform" rating and set a $22.00 target price on shares of Vigil Neuroscience in a research report on Tuesday.November 26, 2024 | marketbeat.comBullish Outlook on Vigil Neuroscience Inc. Amid Promising Clinical Data and Unique TREM2 Biology FocusNovember 21, 2024 | markets.businessinsider.com Remove Ads Get Vigil Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address VIGL Media Mentions By Week VIGL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIGL News Sentiment▼1.890.80▲Average Medical News Sentiment VIGL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIGL Articles This Week▼12▲VIGL Articles Average Week Remove Ads Get Vigil Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HRTX News Today RGNX News Today VERV News Today TECX News Today ORKA News Today MREO News Today BNTC News Today AURA News Today CYRX News Today RNAC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIGL) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vigil Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
